The efficacy and safety of alefacept in psoriatic arthritis

Current Rheumatology Reports

Volumn 8, Issue 5, 2006, Pages 330-331

  Ritchlin, Christopher T ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; CD2 ANTIGEN; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PLACEBO;

ABSENCE OF SIDE EFFECTS; ANTIGEN EXPRESSION; ARTICLE; BODY SURFACE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG INHIBITION; DRUG SAFETY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE ACTIVATION; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 33750415352     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-006-0060-0     Document Type: Article

References (5)

1. Klareskog L, van der Heijde D, de Jager JP, et al.: Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004, 363:675-681.
2. Genentech, Xoma's Raptiva fails to meet endpoint in phase II psoriatic arthritis trial [press release]. Fax Watch: March 22, 2004.
3. Kraan MC, van Kuijk AW, Dinant HJ, et al.: Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum 2002, 46:2776-2784.
4. Bluestone JA, St Clair EW, Turka LA: CTLA4Ig: bridging the basic immunology with clinical application. Immunity 2006, 24:233-238.
5. Abrams JR, Lebwohl MG, Guzzo CA, et al.: CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999, 103:1243-1252.